“The Dark Matter of Psychiatric Genetics”
By Carl Zimmer,
National Geographic
| 12. 20. 2013
The title of my blog post is provocative, I know, but I’m actually just lifting it from the title of a
new commentary in the journal
Molecular Psychiatry by
Thomas Insel, the director of the National Institutes of Mental Health. In his piece, Insel expresses his excitement about a new way of thinking about how genes can contribute to our risk of psychiatric disorders such as schizophrenia. It’s based on an emerging understanding of the human genome that I explored in
a recent story for the
New York Times: each of us does not carry around a single personal genome, but many personal genomes.
When we start out as a single fertilized egg, we have a single genome. When the cell divides in two, there’s a tiny chance that any spot in the DNA will mutate. Over many divisions, the copies of that original genome accumulate mutations and become different from one another. Scientists only now have the tools to dig into this so-called mosaicism and see how different our genomes can become.
Scientists have long known that...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Lucy Tu, The Guardian | 11.05.2025
Beth Schafer lay in a hospital bed, bracing for the birth of her son. The first contractions rippled through her body before she felt remotely ready. She knew, with a mother’s pit-of-the-stomach intuition, that her baby was not ready either...